<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; bans</title>
	<atom:link href="http://www.tapanray.in/tag/bans/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Managing Pharma Investors’ Expectations When The Chips Are Down</title>
		<link>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=managing-pharma-investors-expectations-when-the-chips-are-down</link>
		<comments>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/#comments</comments>
		<pubDate>Sun, 18 Jun 2017 23:34:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[activist]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chips]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Investors]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[Points]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[shareholders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8282</guid>
		<description><![CDATA[Triggered by several critical factors, over a relatively short period of time, a downward spiral is visible with most Indian Pharma stocks, with a significant erosion in market capitalization of many large players in the country. A set of important &#8230; <a href="http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/managing-pharma-investors-expectations-when-the-chips-are-down/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Relevance of Content Marketing In Pharma</title>
		<link>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-relevance-of-content-marketing-in-pharma</link>
		<comments>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/#comments</comments>
		<pubDate>Sun, 11 Jun 2017 23:49:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[environment]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UDFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8268</guid>
		<description><![CDATA[“Nearly half of pharma industry may come under price control” – was the headline of a media report of June 7, 2017. Although, National Pharmaceutical Pricing Authority (NPPA) has apparently denied any such move, the fact is that the number &#8230; <a href="http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-relevance-of-content-marketing-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Even Smaller Countries Now Question Indian Drug Quality Standard</title>
		<link>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=even-smaller-countries-now-question-indian-drug-quality-standard</link>
		<comments>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/#comments</comments>
		<pubDate>Sun, 04 Dec 2016 23:42:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Consumption]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[smaller]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Vietnam]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8001</guid>
		<description><![CDATA[India has over 135 US-FDA approved pharmaceutical manufacturing units, at present. This number is very significant ranking second behind the United States, and was driving the growth of generic drug exports in the top pharma market of the world. Riding &#8230; <a href="http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Happens To Pharma’s Incredible Ride On The ‘Gravy Train’?</title>
		<link>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-happens-to-pharmas-incredible-ride-on-the-gravy-train</link>
		<comments>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/#comments</comments>
		<pubDate>Sun, 25 Sep 2016 23:42:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Entresto]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[gravy]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[incredible]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[Joe]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ride]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[train]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7828</guid>
		<description><![CDATA[India continues to be one of the fastest growing pharmaceutical market of the world with its over 40 percent of the total pharmaceutical produce is exported around the world. Over half of the total exports constitute of formulations, and the &#8230; <a href="http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-happens-to-pharmas-incredible-ride-on-the-gravy-train/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA &#8216;Import Bans&#8217;: Valuing Drug Supply Chain Security for Patients&#8217; Safety</title>
		<link>http://www.tapanray.in/fda-import-bans-valuing-drug-supply-chain-security-for-patients-safety/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fda-import-bans-valuing-drug-supply-chain-security-for-patients-safety</link>
		<comments>http://www.tapanray.in/fda-import-bans-valuing-drug-supply-chain-security-for-patients-safety/#comments</comments>
		<pubDate>Mon, 03 Feb 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DSCS]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pivotal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reinforce]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tylenol]]></category>
		<category><![CDATA[UKMHRA]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4926</guid>
		<description><![CDATA[To strengthen patients’ health and safety requirements, there is a growing need to first work out and then maintain a robust Drug Supply Chain Security (DSCS) mechanism by the pharmaceutical product manufacturers located anywhere in the world. It is, therefore, &#8230; <a href="http://www.tapanray.in/fda-import-bans-valuing-drug-supply-chain-security-for-patients-safety/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fda-import-bans-valuing-drug-supply-chain-security-for-patients-safety/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>USFDA &#8216;Import Bans&#8217;: The Malady Calls For Strong Bitter Pills</title>
		<link>http://www.tapanray.in/usfda-import-bans-the-malady-calls-for-strong-bitter-pills/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=usfda-import-bans-the-malady-calls-for-strong-bitter-pills</link>
		<comments>http://www.tapanray.in/usfda-import-bans-the-malady-calls-for-strong-bitter-pills/#comments</comments>
		<pubDate>Mon, 11 Nov 2013 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[483]]></category>
		<category><![CDATA[adulterated]]></category>
		<category><![CDATA[alert]]></category>
		<category><![CDATA[Ankleshwar]]></category>
		<category><![CDATA[Arcolab]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[Bitter]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[chikalthana]]></category>
		<category><![CDATA[consequences]]></category>
		<category><![CDATA[conspiracy]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[defend]]></category>
		<category><![CDATA[Dewas]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[enforcements]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[Form]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[fudging]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[indefensible]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Lying]]></category>
		<category><![CDATA[malady]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Mohali]]></category>
		<category><![CDATA[Mumbai]]></category>
		<category><![CDATA[Navi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[paonta]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RPG]]></category>
		<category><![CDATA[sahib]]></category>
		<category><![CDATA[sciences]]></category>
		<category><![CDATA[Stride]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[USV]]></category>
		<category><![CDATA[Waluj]]></category>
		<category><![CDATA[warning]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4197</guid>
		<description><![CDATA[It is a matter of pride that Indian pharmaceutical industry is the second largest exporter of drugs and pharmaceuticals globally, generating revenue of around US$ 13 billion in 2012 with a growth of 30 percent (Source: Pharmexcil). Though sounds awkward, &#8230; <a href="http://www.tapanray.in/usfda-import-bans-the-malady-calls-for-strong-bitter-pills/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/usfda-import-bans-the-malady-calls-for-strong-bitter-pills/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
